tris(methyloxycarbonylmethyl)methane | 57056-38-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tris(methyloxycarbonylmethyl)methane
• 英文别名: 3-(methoxycarbonylmethyl)glutaric acid dimethyl ester；Dimethyl 3-(2-methoxy-2-oxoethyl)pentanedioate
• CAS: 57056-38-9
• 化学式: C₁₀H₁₆O₆
• 分子量: 232.233
• InChiKey: GGZYSWCZXIMIIW-UHFFFAOYSA-N

物化性质

• 沸点：
  117-120 °C(Press: 1 Torr)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tris(methyloxycarbonylmethyl)methane 在 lithium aluminium tetrahydride 、 sodium azide 、 palladium 10% on activated carbon 、 氨 、 氢气 、 potassium carbonate 、 甲基磺酰氯 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 180.75h， 生成 bis[N-(1,1-dimethyl-2-N-hydroxyiminepropyl)-2-aminoethyl]-(2-aminoethyl)methane
  参考文献：
  名称：

  Technetium labelled peptides

  摘要：

  本发明涉及包含放射性标记的c-Met结合肽的锝显像剂，适用于体内SPECT或PET显像。这些c-Met结合肽通过螯合物结合进行标记。还披露了制剂、药物组合物的制备方法，以及使用这些组合物进行体内显像的方法，特别适用于癌症诊断。

  公开号：

  US09259496B2
• 作为产物：
  描述：

  2-cyano-3-methoxycarbonylmethyl-glutaric acid dimethyl ester 在 盐酸 、 氯化亚砜 作用下， 以 水 为溶剂， 反应 17.0h， 生成 tris(methyloxycarbonylmethyl)methane
  参考文献：
  名称：

  Methanetriacetic and methylmethanetriacetic acids, their precursors and derivatives: NMR and X-ray diffraction studies

  摘要：

  The NMR spectra and crystal structures of triacid 2b, triamide 4b and diastereomers 7, 8 were studied; the crystal structure of 2b is the first example of an H-bonded totally interlocked and percatenated homochiral structure.

  DOI：

  10.1070/mc2005v015n05abeh002164

文献信息

• STABILIZER COMPOUND, LIQUID CRYSTAL COMPOSITION, AND DISPLAY ELEMENT
  申请人：DIC CORPORATION

  公开号：US20180230094A1

  公开（公告）日：2018-08-16

  The present invention provides a compound represented by General Formula (I). The compound according to the present invention prevents the liquid crystal composition from being deteriorated due to light, has high compatibility with the liquid crystal composition, and does not impair the storage stability of the liquid crystal composition, thus the compound is useful as a constituent member of a liquid crystal composition. Since the liquid crystal composition and the liquid crystal display element containing the compound of the present invention exhibit UV resistance and have a high VHR, it is possible to obtain a liquid crystal display element with excellent display quality in which display defects such as burn-in and display unevenness do not occur or are suppressed.

  本发明提供了一种由通式（I）表示的化合物。根据本发明的化合物可以防止液晶组合物因光照而恶化，与液晶组合物具有高兼容性，并不会损害液晶组合物的储存稳定性，因此该化合物作为液晶组合物的组成部分是有用的。由于含有本发明化合物的液晶组合物和液晶显示元件表现出UV抵抗性，并具有高VHR，因此可以获得具有优异显示质量的液晶显示元件，其中不会发生或被抑制烧屏和显示不均匀等显示缺陷。
• [EN] INHIBITOR IMAGING AGENTS<br/>[FR] AGENTS INHIBITEURS D'IMAGERIE
  申请人：AMERSHAM PLC

  公开号：WO2005049005A1

  公开（公告）日：2005-06-02

  The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi's) of the sulphonamide hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body.

  本发明揭示了一种成像试剂，其中包括一种特定类型的矩阵金属蛋白酶抑制剂（MMPi's），属于磺胺基羟肟类，并标记有成像基团，可用于哺乳动物体内成像和诊断的诊断成像试剂。
• Novel Imaging Agents for Fibrosis
  申请人：Chettibi Salah

  公开号：US20080279765A1

  公开（公告）日：2008-11-13

  The present invention provides a novel imaging agent targeting the mannose-6-phosphate (M6P) receptor suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. The invention also provides a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which the mannose-6-phosphate receptor is upregulated is provided.

  本发明提供了一种新型的成像剂，针对甘露糖-6-磷酸（M6P）受体，适用于非侵入性可视化纤维化。本发明还提供了一种用于制备成像剂的方法，以及用于该方法的前体。本发明还提供了包括成像剂的药物组合物以及用于制备药物组合物的工具包。在另一个方面，本发明提供了利用成像剂进行体内成像和制备用于诊断甘露糖-6-磷酸受体上调病况的药物的方法。
• Diagnostic imaging agents with mmp inhibitory activity
  申请人：Storey Anthony

  公开号：US20070071670A1

  公开（公告）日：2007-03-29

  The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the diagnostic imaging agent of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be used in the diagnosis of diseases where specific matrix metalloproteinases are known to be involved.

  本发明涉及诊断成像领域。具体来说，该发明涉及已知涉及特定基质金属蛋白酶的疾病的诊断成像。该发明的一个实施例是一种具有适用于诊断成像的基质金属蛋白酶抑制活性的化合物。本发明还揭示了一种包含该发明的诊断成像试剂的药物组合物，其适合于哺乳动物的给药形式。此外，该发明还揭示了用于合成该发明的诊断成像试剂的中间体以及用于制备该发明的药物组合物的试剂盒。该发明的药物组合物可用于诊断已知涉及特定基质金属蛋白酶的疾病。
• Radiopharmaceutical compositions
  申请人：Barnett David Jonathan

  公开号：US10758635B2

  公开（公告）日：2020-09-01

  The present invention relates to 99mTc-maraciclatide radiopharmaceutical compositions, which are stabilised with a radioprotectant. Also described are kits for the preparation of the radiopharmaceutical compositions, as well methods of preparing such compositions from the kit. The invention also includes methods of imaging the mammalian body using the radiopharmaceutical compositions.

  本发明涉及稳定化了放射保护剂的99mTc-maraciclatide放射性药物组合物。还描述了用于制备放射性药物组合物的试剂盒，以及从试剂盒中制备这种组合物的方法。该发明还包括使用这些放射性药物组合物对哺乳动物体进行成像的方法。